Project Director: Allison Eddy, M.D.
Consultant: Scott Turner, Ph.D.
CKD is a major risk factor for cardiovascular disease (5x increased risk). An estimated 28 million adult Americans have CKD; a subset (currently > 500,000) will survive long enough to need dialysis or a kidney transplant. At this time, no therapy is known to have a clinically significant impact on CKD progression rates. The goal of the proposed research is to develop a scientific foundation and rationale for new CKD therapies.
© 2010-2018. All Rights Reserved to Vanderbilt University. Vanderbilt University is committed to principles of equal opportunity and affirmative action.
Released April 5, 2018